Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05529550
Other study ID # insulin-like growth factor-1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date December 1, 2021

Study information

Verified date September 2022
Source Menoufia University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Many studies done on children with thalassemia have shown a variable prevalence of defective IGF-I concentrations have been shown to be low in the majority of children, with or without GH deficiency. The Aim of this study to assess nutritional status and role of Insulin-like growth factor 1 (IGF-1) and its associating factors in children with thalassemia major


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date December 1, 2021
Est. primary completion date November 1, 2021
Accepts healthy volunteers
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria: - Children in the age group of 2-18 years with confirmed diagnosis of Beta thalassemia major. Exclusion Criteria: - Children with other chronic diseases (cardiac, renal, vascular) - Children with malignancy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Samar Abd El-Hameed Shibin Al Kawm

Sponsors (1)

Lead Sponsor Collaborator
Menoufia University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary IGF-1 insulin-like growth factor-1 which measured by enzyme linked immunosorbent assay (ELISA). at the time of recruitment
See also
  Status Clinical Trial Phase
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT04614779 - Long-term Clinical Study of CN128 in Thalassemia Patients Phase 2
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT02995707 - The Effective and Safety of Thalidomide in NTDT Phase 2
Active, not recruiting NCT01935661 - A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT00901199 - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Phase 2
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Active, not recruiting NCT03655678 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia Phase 2/Phase 3
Recruiting NCT05508932 - Atrial Fibrillation in Beta-Thalassemia
Completed NCT03609827 - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed NCT03095326 - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Phase 4
Completed NCT03117192 - Zinc Supplementation on Cellular Immunity in Thalassemia Major Phase 4
Completed NCT01443312 - Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
Completed NCT00744692 - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Phase 1
Completed NCT00235391 - Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Phase 3
Not yet recruiting NCT06058260 - Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital
Completed NCT04582110 - The Role of OCTA in Patients Affected by Beta Thalassemia
Recruiting NCT06213402 - RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A